
A new health policy paper published in The Lancet Regional Health – Europe calls for decisive action to transform how Europe monitors noncommunicable diseases (NCDs). Developed collectively by the Joint Action on Cardiovascular Diseases and Diabetes (JACARDI), the Joint Action Prevent Non-Communicable Diseases (JA PreventNCD), and the WHO Regional Office for Europe (WHO/Europe), the document sets out five priority actions to strengthen health surveillance systems across the region, an essential step in curbing the growing burden of NCDs and mental health and ensuring more effective and equitable health care.
The publication, entitled “Strengthening noncommunicable disease surveillance systems in Europe through a collaborative, multi-stakeholder approach: a key priority for advancing evidence-based policymaking,” comes at a critical time following the Fourth United Nations High-Level Meeting on NCDs and Mental Health.
“Europe has a unique opportunity and responsibility to recommit to evidence-based health governance, with sustained investment in resilient NCD surveillance systems,” explain the authors of the publication.
Dr. Bueno: “Data is not just numbers; it is the basis for designing policies that reduce inequalities and improve the health of the entire population”
Dr. Héctor Bueno, one of the authors of the document and leader of the JACARDI working group on data availability and quality, emphasizes the importance of coordinating and strengthening health information systems in order to achieve continuous, systematic, and standardized monitoring that will ensure more effective and equitable policies. “To advance the fight against NCDs, we need information systems that are robust, inclusive, and sustainable. Data are not just numbers; they are the basis for designing policies that reduce inequalities and improve the health of the entire population”.
The coordinator of the Cardiovascular Research Area at the Instituto de Investigación i+12 and head of the Multidisciplinary Translational Cardiovascular Research Group at i+12 at the Hospital Universitario 12 de Octubrein Madrid, and leader of a research group at the Spanish National Center for Cardiovascular Research (CNIC), insists that “it is time to invest in robust and collaborative surveillance systems so that healthcare decisions are based on real evidence and have a lasting impact on people’s health.”
The publication highlights five critical areas where action is needed to make monitoring systems stronger, fairer, and more effective. It calls for collecting data that is truly inclusive and disaggregated, so that inequalities become visible and can be addressed. It stresses the importance of solid governance, clear legal frameworks, and long-term investment to ensure that progress is sustained.
Monitoring, the authors argue, should also be embedded in real-time policymaking, so that information directly shapes decisions and drives accountability. Civil society, communities, people with lived experience, and marginalized groups should have a meaningful voice in this process, making sure that data reflects people’s lived realities. And finally, the paper points to the need for stronger collaboration across sectors, greater sharing of knowledge, and more capacity building to secure lasting impact.
80% of NCDs can be prevented through effective public health policies and early detection strategies
“Tackling NCDs is one of five priorities of WHO/Europe’s Second European Programme of Work, co-created with 53 Member States and shaped through broad public consultations, including with health professionals, people living with NCDs and civil society. Effective action on NCDs hinges on good data. Europe can lead by example and showcase collaborative and inclusive approaches together with key stakeholders, including EU Joint Actions”, said Dr. Gundo Weiler, Director of the Division of Prevention and Health Promotion at WHO Regional Office for Europe.
An estimated 80% of NCDs are considered preventable through effective public health policies and early detection strategies. These figures underscore the urgent need for a paradigm shift from a model centred on diagnostics and treatment to one rooted in prevention, health promotion, and evidence-based screening.
Despite great efforts in international commitments, progress at the national level has been inconsistent. Monitoring systems remain fragmented, overly reliant on short-term projects, or challenged by limited governance and insufficient investment. This has created a critical gap between ambitious global targets and their translation into actionable national policies.
The policy paper identifies persistent data gaps, structural weaknesses, and opportunities for innovation. It emphasizes that monitoring is not just about collecting data, it is about ensuring that information is used in real time to drive policy reform, accountability, and equity.
Lessons from Europe
The authors underline that too often, NCD monitoring efforts have been ad hoc, reliant on external funding or driven by individual champions. This has led to uneven coverage, lack of comparability between countries, and persistent blind spots when it comes to the health of groups living in vulnerable situations, such as migrants, minorities, and people with disabilities.
Without data that is disaggregated and reflects disparities, inequalities remain invisible and policies risk reinforcing exclusion. The authors argue that equity must be at the center of all future monitoring efforts.
Dra. Armocida: “We should begin to view data not only as numbers, but as reflections of lives and human rights”
“It is a moral and ethical imperative to advocate for and generate more inclusive data. Data should be systematically disaggregated by age, sex, gender, geography, socioeconomic status, disability, ethnic and migration background to reveal territorial disparities and enable place-based interventions”, unfolds Dr. Benedetta Armocida, from the Department of Cardiovascular, Endocrine-metabolic Diseases and Aging at Istituto Superiore di Sanità-ISS, Rome (Italy) and Coordinator of JACARDI.
“We should begin to view data not merely as numbers, but as reflections of human lives and rights: each data point tells a story, and data becomes truly powerful when it shifts narratives, amplifies the voices of those too often overlooked, and holds systems accountable. Data must be observed critically and translated into policies that strengthen health systems. Without inclusive monitoring, structural inequities remain concealed, and the most vulnerable remain invisible—one data point, one life, one missed opportunity at a time”, adds Dr Armocida.
At the same time, the authors highlight successful innovations and good practices emerging from European Joint Actions, such as JACARDI and JA PreventNCD, demonstrating that progress is possible when commitments are matched by clear governance, adequate investment, and cross-sector collaboration.
“Across Europe we already see solutions that work. Joint Actions like JA PreventNCD and JACARDI help countries align methods, share tools and learn faster from each other. That is how we improve comparability between countries and make monitoring more useful for prevention and health promotion, including by showing more clearly where inequalities persist,” says Professor Knut-Inge Klepp, from the Norwegian Institute of Public Health, Oslo and Scientific Coordinator of JA PreventNCD.
“But we have to treat monitoring as core infrastructure, not an extra task. It needs stable funding, clear governance and the ability to produce data that is timely and inclusive. If monitoring depends on short-term projects or individual champions, it will remain uneven. If it is institutionalized, it can guide priorities, strengthen accountability and help sustain progress over time,” adds Klepp.
Europe has both a responsibility and an opportunity to lead the way in building stronger, more inclusive health information systems that can serve as a global benchmark. Doing so will be critical not only to reducing premature mortality from NCDs by one-third by 2030, but also to ensuring health equity and resilience in the face of future challenges. “Because what gets measured gets prioritised. What gets disaggregated gets addressed. And what gets institutionalised can be sustained”, conclude the authors.
Benedetta Armocida, Hanna Tolonen, Ivo Rakovac, Beatrice Formenti, Jill Farrington, Allison Ekberg, Hector Bueno, Giovanni Capelli, Silvia Francisci, Morten S. Frydensberg, Ane Fullaondo, Linda Granlund, Yhasmine Hamu Azcarate, Torben F. Hansen, Emil Høstrup, Tomi Mäki-Opas, Luigi Palmieri, Markku Peltonen, Valentina Possenti, Marco Silano, Gundo Weiler, Kremlin Wickramasinghe, Edwin Wouters, Knut-Inge Klepp, Graziano Onder, Gauden Galea, Strengthening non-communicable diseases monitoring systems in Europe through a multistakeholder collaborative approach: a key priority for advancing data-driven policymaking, The Lancet Regional Health – Europe, Volume 61, 2026, 101553, ISSN 2666-7762, https://doi.org/10.1016/j.lanepe.2025.101553
Abstract: TBA
La entrada IMDEA Energía celebra la 14ª edición del workshop de jóvenes investigadores se publicó primero en IMDEA ENERGÍA.
Biopharmaceutical company Oniria Therapeutics, Vall d’Hebron Institute of Oncology (VHIO) and Institut Català d’Investigació Química (ICIQ) will work together on the regulatory preclinical phase for ONR-001 and develop the drug up to its first clinical trial in patients.
ONR-001 is an innovative therapy from Oniria Therapeutics designed for malignant tumors that do not respond to current treatments.
Biopharmaceutical company Oniria Therapeutics, Vall d’Hebron Institute of Oncology (VHIO) and Institut Català d’Investigació Química (ICIQ) have joined forces to advance development of ONR-001, a new drug to treat colorectal cancer (CRC), and prepare it for clinical trials. ONR-001 is an innovative therapy developed by Oniria Therapeutics targeting aggressive solid and hematologic tumors that don’t respond to current treatments.
For this purpose, a public-private consortium has been established that will receive €1,772,651 in funding from the Spanish Ministry of Science, Innovation and Universities and the European Union, through the CPP 2024 program. These funds will be used to carry out the whole regulatory preclinical phase with ONR-001, which includes conducting more experiments to demonstrate its efficacy in colorectal cancer, developing the Chemistry, Manufacturing and Controls (CMC) strategy and executing the regulatory preclinical studies needed to demonstrate its safety.
What sets ONR-001 apart from other therapies is that it hyperactivates the TET2 enzyme to a level that is lethal to persistent tumor cells, acting as an Achilles’ heel that, in preclinical studies, has been shown to significantly inhibit the progression of colon cancer, metastatic melanoma and acute myeloid leukemia. TET2 is a tumor suppressor gene that, when hyperactivated, leaves a mark in the DNA of tumor cells, forcing them to alter their function. Unable to adapt, the malignant cells die. This strategy, based on controlled activation of a protective gene, is a completely new approach to cancer treatment.
Colorectal cancer, one of the leading causes of cancer mortality
With approximately 1.9 million new cases and 900,000 deaths each year, colorectal cancer is the third most commonly diagnosed cancer in the world and one of the leading causes of cancer-related mortality, according to the World Health Organization (WHO). In Spain, it is even more significant, as the most frequent type of malignant tumor: 41,167 new cases were diagnosed in 2024 alone, according to the Spanish Association Against Cancer.
“Tumor resistance and recurrence, often caused by cancer cells that survive initial therapies, are two of the greatest obstacles in treating colorectal cancer. With ONR-001, we are pursuing a targeted strategy to help overcome these challenges and improve long-term patient outcomes,” explains Dr. Hector G. Palmer, chief scientific officer and co-founder of Oniria Therapeutics, and head of the VHIO Stem Cells and Cancer Group.
“Collaborations like this are essential to facilitate the exchange of knowledge between research centers, in our case in chemical research applied to health, and the biomedical industry, helping accelerate innovative therapies that can benefit millions of patients,” notes Dr. Fernando Bravo, Knowledge and Technology Transfer (KTT) manager at ICIQ.
“The whole Oniria Therapeutics team is excited to see that this project will allow us to take ONR-001 to Phase I clinical trials in 2027 and that we are moving forward according to the business plan to make it an effective new therapy for various tumors that are resistant to current treatments,” concludes Esther Riambau, CEO and co-founder of Oniria Therapeutics.
At the same time, the biopharmaceutical company is also working to bring ONR-001 to the clinical phase for patients with metastatic melanoma and other indications where evidence of efficacy has already been obtained.
In 2024, Oniria Therapeutics was named one of the 10 most disruptive companies by the Government of Catalonia (ACCIÓ) and received the Catalan Society of Biology Award for its outstanding work to overcome cancer persistence.

Project CPP2024-011292 funded by MICIU/AEI/10.13039/501100011033/FEDER, EU.
About Oniria Therapeutics
Oniria Therapeutics is a biopharmaceutical company in the preclinical phase that is developing innovative precision drugs to eliminate persistent tumor cells, which are responsible for patients progressing into the fatal phases of cancer. The company was established in 2021 as a spinoff of the Vall d’Hebron Institute of Oncology (VHIO), University of Barcelona (UB) and Catalan Institution for Research and Advanced Studies (ICREA) by Dr. Héctor G. Palmer, Esther Riambau, Dr. Isabel Puig, Dr. Josep Tabernero, Dr. Xavier Barril and Dr. Carles Galdeano. Oniria headquarters is in the Cellex Center on the Vall d’Hebron Hospital campus in Barcelona. It has received support from investors (Botín Foundation and Banco Sabadell BStartup), business angels and organizations in the health and biomedicine sector (Spanish Association Against Cancer and the ”La Caixa” Foundation). More information: www.oniriatherapeutics.com
About VHIO
The Vall d’Hebron Institute of Oncology (VHIO), created in 2006 and integrated into the Vall d’Hebron Campus, is a benchmark center in personalized medicine in oncology. Our goal is to carry out research to improve the prevention, early diagnosis and treatment of cancer thanks to a pioneering model of translational research that consists of transforming the latest discoveries in the lab into early phase clinical trials and, therefore, into new, more effective treatments that improve quality of life for cancer patients. VHIO is a member of the CERCA system and an accredited Severo Ochoa Center of Excellence. None of the VHIO activities would be possible without the support of our patrons —Government of Catalonia, Cellex Foundation, FERO Foundation, ”la Caixa” Foundation, BBVA Foundation and CRIS Cancer Foundation— and donations from all the associations, entities and individuals who contribute generously so that we can advance in cancer research. More information: https://vhio.net
La entrada Oniria Therapeutics, VHIO and ICIQ awarded over €1.7 million from Spanish Ministry of Science and Innovation to advance drug targeting resistant colon cancer se publicó primero en ICIQ.

The congress, co-organised by ICN2, featured strong participation from the institute’s researchers and offered a broad programme focused on the latest advances in nanotechnology and biomedicine.

